US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.82

-0.0200-1.09%

Post-market: 1.78-0.0400-2.20%19:38 EDT

Volume:186.59K

Turnover:335.11K

Market Cap:51.14M

PE:-2.22

High:1.87

Open:1.79

Low:1.73

Close:1.84

Loading ...

Overview Company News Filings

Lake Street Sticks to Its Buy Rating for OS Therapies Incorporated (OSTX)

OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy

Os Therapies Partners With Eversana for the U.S. Commercialization of Ost-Her2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

THOMSON REUTERS

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies: Company Is Preparing for Late Stage Clinical Development of Other Pipeline Candidates

THOMSON REUTERS

Os Therapies Submits Request for Regenerative Medicine Advanced Therapy (Rmat) Designation to U.S. FDA for Ost-Her2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

THOMSON REUTERS

Os Therapies: Upon Receipt of Type D Meeting Feedback Co Intends to Promptly Request End of Phase 2 Meeting With FDA

THOMSON REUTERS

OS Therapies Inc. Awaits FDA Feedback for RMAT Designation and Plans Rolling BLA Submission for OST-HER2 in Pediatric Osteosarcoma Prevention

OS Therapies files to sell 7.49M shares of common stock for holders

BRIEF-Os Therapies Files For Offering Of Up To 7.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy

BRIEF-Os Therapies Reports First Quarter 2025 Financial Results

OS Therapies Q1 EPS $(0.18) Misses $(0.09) Estimate

OS Therapies Inc. Reports Q1 2025 Loss of $3.876M, EPS Improves to $0.18 Despite Increased Expenses

Os Therapies Inc - on Track for Q3 2025 Bla Filing for Ost-Her2

THOMSON REUTERS

Os Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Launches OS Animal Health Subsidiary to Target Canine Osteosarcoma Market

Shalom Auerbach, 10% Owner, Reports Disposal of Common Shares of OS Therapies Inc

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OSTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.82,"timestamp":1749844800000,"preClose":1.84,"halted":0,"volume":186589,"hourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"delay":0,"floatShares":18778400,"shares":28097697,"eps":-0.819717,"marketStatus":"Market Closed","change":-0.02,"latestTime":"06-13 16:00:00 EDT","open":1.79,"high":1.87,"low":1.73,"amount":335107.0521604,"amplitude":0.076087,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.819717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.7802,"preClose":1.863,"latestTime":"09:27 EDT","volume":10344,"amount":18630.5763312,"timestamp":1749821265289},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"volumeRatio":0.31820578656515647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":18778400,"roa":"-263.81%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.31820578656515647,"shares":28097697,"dividePrice":0,"high":1.87,"amplitude":0.076087,"preClose":1.84,"low":1.73,"week52Low":1.12,"pbRate":"-12.21","week52High":7,"institutionHeld":0,"latestPrice":1.82,"eps":-0.819717,"divideRate":0,"volume":186589,"delay":0,"ttmEps":-0.819717,"open":1.79,"prevYearClose":4.28,"prevWeekClose":1.67,"prevMonthClose":1.53,"prevQuarterClose":1.54,"fiveDayClose":1.67,"twentyDayClose":1.66,"sixtyDayClose":1.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542582945","title":"Lake Street Sticks to Its Buy Rating for OS Therapies Incorporated (OSTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2542582945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542582945?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:55","pubTimestamp":1749646523,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on OS Therapies Incorporated (OSTX – Research Report) today and set a price target of $19.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-os-therapies-incorporated-ostx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-os-therapies-incorporated-ostx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2542425319","title":"OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2542425319","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542425319?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:40","pubTimestamp":1749555643,"startTime":"0","endTime":"0","summary":"OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2QlL18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2542319447","title":"Os Therapies Partners With Eversana for the U.S. Commercialization of Ost-Her2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2542319447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542319447?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:40","pubTimestamp":1749555631,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nFWN3SC0R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2542384106","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2542384106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542384106?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:22","pubTimestamp":1749471720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2025 08:22 ET (12:22 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2541854787","title":"Os Therapies: Company Is Preparing for Late Stage Clinical Development of Other Pipeline Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2541854787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541854787?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:30","pubTimestamp":1749209419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80UC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":1},{"id":"2541854238","title":"Os Therapies Submits Request for Regenerative Medicine Advanced Therapy (Rmat) Designation to U.S. FDA for Ost-Her2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2541854238","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541854238?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:30","pubTimestamp":1749209419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2541854219","title":"Os Therapies:  Upon Receipt of Type D Meeting Feedback Co Intends to Promptly Request End of Phase 2 Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2541854219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541854219?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:30","pubTimestamp":1749209419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80UC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2541685446","title":"OS Therapies Inc. Awaits FDA Feedback for RMAT Designation and Plans Rolling BLA Submission for OST-HER2 in Pediatric Osteosarcoma Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2541685446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541685446?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:30","pubTimestamp":1749209416,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Awaits FDA Feedback for RMAT Designation and Plans Rolling BLA Submission for OST-HER2 in Pediatric Osteosarcoma Prevention. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Business Wire  on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5VNC0w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2537157406","title":"OS Therapies files to sell 7.49M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2537157406","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537157406?lang=en_us&edition=fundamental","pubTime":"2025-05-24 05:15","pubTimestamp":1748034927,"startTime":"0","endTime":"0","summary":"17:13 EDT OS Therapies (OSTX) files to sell 7.49M shares of common stock for holders Published first on TheFly – the ultimate source for real-time,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-files-to-sell-7-49m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-files-to-sell-7-49m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2537152028","title":"BRIEF-Os Therapies Files For Offering Of Up To 7.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537152028","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537152028?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:57","pubTimestamp":1748033848,"startTime":"0","endTime":"0","summary":"BRIEF-Os Therapies Files For Offering Of Up To 7.5 Million Shares Of Common Stock By Selling Stockholders - SEC FilingOS Therapies Inc OSTX.A:OS THERAPIES: FILES FOR OFFERING OF UP TO 7.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text: [ID:n0001213900-25-047395]Further company coverage: OSTX.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV0Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2537304919","title":"Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537304919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537304919?lang=en_us&edition=fundamental","pubTime":"2025-05-22 00:25","pubTimestamp":1747844721,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated (OSTX – Research Report), with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-os-therapies-promising-developments-and-strategic-positioning-in-cancer-immunotherapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-os-therapies-promising-developments-and-strategic-positioning-in-cancer-immunotherapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2535396208","title":"BRIEF-Os Therapies Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535396208","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535396208?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:33","pubTimestamp":1747395230,"startTime":"0","endTime":"0","summary":"BRIEF-Os Therapies Reports First Quarter 2025 Financial Results May 16 (Reuters) - OS Therapies Inc OSTX.A:OS THERAPIES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEOS THER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nTUA2RZ5P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2535642313","title":"OS Therapies Q1 EPS $(0.18) Misses $(0.09) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535642313","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535642313?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:03","pubTimestamp":1747389801,"startTime":"0","endTime":"0","summary":"OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.09) by 100 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45463283/os-therapies-q1-eps-0-18-misses-0-09-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2535936412","title":"OS Therapies Inc. Reports Q1 2025 Loss of $3.876M, EPS Improves to $0.18 Despite Increased Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2535936412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535936412?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:00","pubTimestamp":1747389618,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Business Wire  on May 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDLTWf5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXS","OSTX"],"gpt_icon":0},{"id":"2535642883","title":"Os Therapies Inc - on Track for Q3 2025 Bla Filing for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2535642883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535642883?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:00","pubTimestamp":1747389600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nTUA2RZ5P2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2535636451","title":"Os Therapies Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535636451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535636451?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:00","pubTimestamp":1747389600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nTUA2RZ5P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2535232364","title":"Press Release: OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535232364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535232364?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:00","pubTimestamp":1747389600,"startTime":"0","endTime":"0","summary":"-- Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm. statistical analysis methods to support pending Accelerated Approval,Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation. -- Completed Phase 2b trial data analysis using methods agreed to by FDA to. -- Company remains on track for Q3 2025 BLA filing for OST-HER2 in the. prevention of recurrent, fully resected, lung metastatic pediatric. OS Therapies Inc.  , a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended March 31, 2025 and provided a business update.\"As outlined in communications surrounding our 2024 Annual Report on Form 10-K, the first quarter saw some significant one-time expenses related to closing out the treatment phase of the Phase 2b trial, as well as start-up costs for regulatory preparations ahead of our submission,\" said Chris Acevedo, Chief Financial Officer of OS Therapies. \"Those ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","BK4158","BK4080","BK4588","BK4585","BK4017","SAM","ADC","OSTX","DC","BK4231"],"gpt_icon":0},{"id":"2535879769","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2535879769","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535879769?lang=en_us&edition=fundamental","pubTime":"2025-05-16 01:48","pubTimestamp":1747331280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 13:48 ET (17:48 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2535149618","title":"OS Therapies Inc. Launches OS Animal Health Subsidiary to Target Canine Osteosarcoma Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2535149618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535149618?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:00","pubTimestamp":1747303250,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced the formation of a new subsidiary, OS Animal Health, Inc., to commercialize OST-HER2 for the treatment of canine osteosarcoma. This strategic move aims to capitalize on the substantial market opportunity in veterinary oncology, with the canine osteosarcoma market valued at approximately $1.35 billion. OS Animal Health will operate independently from OS Therapies, with separate funding and a focus on re-establishing USDA conditional approval for OST-HER2, targeting submission in the latter half of 2025. This development follows recent positive clinical data and a new patent protecting the commercial manufacturing process for OST-HER2, securing its platform until 2040.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL4J5Dbp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2534125524","title":"Shalom Auerbach, 10% Owner, Reports Disposal of Common Shares of OS Therapies Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2534125524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534125524?lang=en_us&edition=fundamental","pubTime":"2025-05-10 09:30","pubTimestamp":1746840650,"startTime":"0","endTime":"0","summary":"Shalom Auerbach, a 10% owner, reported a disposal of common shares of OS Therapies Inc. The form was filed by more than one reporting person, including Auerbach and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250510:nNDL9n5d9r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":105,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-06-13","current":-4.574874,"percent":0.80543,"low":-14.897496,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"high":-2.731469,"avg":-7.723832,"sd":3.415038,"marketCap":51699762},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762}],"updateTime":1749952039380}}}